| Symbol | CRVS |
|---|---|
| Name | CORVUS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 901 GATEWAY BOULEVARD,THIRD FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 900-4520 |
| Fax | — |
| — | |
| Website | https://www.corvuspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001626971 |
| Description | Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The companys lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant. Additional info from NASDAQ: |
Chan Andrew C. 🟢 acquired 30.0K shares (1 derivative) of Corvus Pharmaceuticals, Inc. (CRVS) at $16.02 Transaction Date: Apr 23, 2026 | Filing ID: 000149
Read moreNew Form 3 - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001610717-26-000148 <b>Size:</b> 9 KB
Read moreNew Form DEFA14A - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048600 <b>Size:</b> 454 KB
Read moreCorvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
Read moreCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Read more(99% Neutral) CORVUS PHARMACEUTICALS, INC. (CRVS) Announces Business Combination
Read moreNew Form 424B5 - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001104659-26-027382 <b>Size:</b> 527 KB
Read moreNew Form S-3ASR - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001104659-26-027362 <b>Size:</b> 906 KB
Read more(85% Positive) CORVUS PHARMACEUTICALS, INC. (CRVS) Reports Q1 2026 Financial Results
Read moreCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Phase2 | Atopic Dermatitis | Recruiting | 2026-02-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Perip… | Phase3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recruiting | 2024-10-02 | 2028-12-01 | ClinicalTrials.gov |
| NCT06345404 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants … | Phase1 | Atopic Dermatitis | Completed | 2024-04-16 | 2026-02-24 | ClinicalTrials.gov |
| NCT04734873 | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to M… | Phase3 | Covid-19 | Terminated | 2021-02-25 | 2021-08-18 | ClinicalTrials.gov |
| NCT04464395 | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | Phase1 | COVID-19 | Completed | 2020-07-01 | 2021-07-09 | ClinicalTrials.gov |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed… | Phase1 | Multiple Myeloma | Completed | 2020-02-20 | 2022-03-01 | ClinicalTrials.gov |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lympho… | Phase1 | T-cell Lymphoma | Active_Not_Recruiting | 2019-05-03 | 2026-04-30 | ClinicalTrials.gov |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for P… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2018-04-25 | 2023-02-19 | ClinicalTrials.gov |
| NCT03237988 | Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 i… | Phase1 | Healthy Subjects | Completed | 2017-07-20 | 2017-10-04 | ClinicalTrials.gov |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone … | Phase1 | Renal Cell Cancer | Completed | 2016-01-01 | 2021-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard of Care | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-006 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-444 Tablets | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| CPI-444 Capsules | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| Ciforadenant + atezolizumab | Other | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| Ciforadenant | Other | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| daratumumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| Ciforadenant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| Placebo + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 1 mg/kg + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 2 mg/kg + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 + pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 + ciforadenant | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-818 | Other | Phase PHASE1 | T-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT03952078 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Soquelitinib | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06345404 |
| Soquelitinib | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06345404 |
| Pralatrexate | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Belinostat | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Soquelitinib | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Pralatrexate | DRUG | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Belinostat | DRUG | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Placebo | DRUG | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Soquelitinib | DRUG | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Placebo + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 1 mg/kg + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 2 mg/kg + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| Standard of Care | OTHER | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| daratumumab | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| CPI-818 | DRUG | Phase PHASE1 | T-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT03952078 |
| CPI-006 + pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 + ciforadenant | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 | DRUG | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-444 Tablets | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| CPI-444 Capsules | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| Ciforadenant + atezolizumab | DRUG | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| Ciforadenant | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |